XPEL vs. CPRX

Last updated Jun 4, 2026

XPEL (XPEL, Inc.) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. XPEL operates in Auto Parts (Consumer Cyclical), while CPRX operates in Biotechnology (Healthcare). Over the past 10 years, XPEL returned 46.29%/yr vs 48.24%/yr for CPRX. At a 0.10 correlation, their price movements are largely independent.

Performance

XPEL vs. CPRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in XPEL, Inc. (XPEL) and Catalyst Pharmaceuticals, Inc. (CPRX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, XPEL achieves a -9.32% return, which is significantly lower than CPRX's 34.02% return. Both investments have delivered pretty close results over the past 10 years, with XPEL having a 46.29% annualized return and CPRX not far ahead at 48.24%.

XPEL

• 1D: 1.16%
• 1M: -5.55%
• YTD: -9.32%
• 6M: -6.45%
• 1Y: 21.99%
• 3Y*: -15.05%
• 5Y*: -12.55%
• 10Y*: 46.29%

CPRX

• 1D: 0.03%
• 1M: 8.09%
• YTD: 34.02%
• 6M: 35.41%
• 1Y: 25.57%
• 3Y*: 39.39%
• 5Y*: 41.68%
• 10Y*: 48.24%

*Multi-year figures are annualized to reflect compound growth (CAGR)

XPEL vs. CPRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
XPEL XPEL, Inc.	-9.32%	24.96%	-25.83%	-10.34%	-12.04%	32.43%	251.95%	140.10%	335.82%	0.00%
CPRX Catalyst Pharmaceuticals, Inc.	34.02%	11.84%	24.15%	-9.62%	174.74%	102.69%	-10.93%	95.31%	-50.90%	272.38%

Correlation

The correlation between XPEL and CPRX is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.17
Correlation (3Y) Calculated over the trailing 3-year period	0.29
Correlation (5Y) Calculated over the trailing 5-year period	0.32
Correlation (10Y) Calculated over the trailing 10-year period	0.18
Correlation (All Time) Calculated using the full available price history since Jul 19, 2007	0.10

The correlation between XPEL and CPRX shifts across timeframes, from 0.10 (all time) to 0.32 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap XPEL : $1.25B CPRX : $3.97B
EPS XPEL : $1.91 CPRX : $1.74
PE Ratio XPEL : 23.64 CPRX : 17.98
PEG Ratio XPEL : 1.65 CPRX : 0.32
PS Ratio XPEL : 2.56 CPRX : 6.67
PB Ratio XPEL : 4.28 CPRX : 3.92
Total Revenue (TTM) XPEL : $489.75M CPRX : $596.96M
Gross Profit (TTM) XPEL : $208.35M CPRX : $378.23M
EBITDA (TTM) XPEL : $78.35M CPRX : $313.50M

Return for Risk

XPEL vs. CPRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XPEL

XPEL Risk / Return Rank: 56
XPEL Sharpe Ratio Rank: 59
XPEL Sortino Ratio Rank: 55
XPEL Omega Ratio Rank: 53
XPEL Calmar Ratio Rank: 56
XPEL Martin Ratio Rank: 58

CPRX

CPRX Risk / Return Rank: 60
CPRX Sharpe Ratio Rank: 65
CPRX Sortino Ratio Rank: 59
CPRX Omega Ratio Rank: 59
CPRX Calmar Ratio Rank: 60
CPRX Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XPEL vs. CPRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for XPEL, Inc. (XPEL) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XPEL	CPRX	Difference
Sharpe ratio Return per unit of total volatility	0.55	0.76	-0.22
Sortino ratio Return per unit of downside risk	1.04	1.25	-0.21
Omega ratio Gain probability vs. loss probability	1.13	1.16	-0.03
Calmar ratio Return relative to maximum drawdown	0.69	0.94	-0.25
Martin ratio Return relative to average drawdown	1.66	1.71	-0.05
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XPEL vs. CPRX - Sharpe Ratio Comparison

The current XPEL Sharpe Ratio is 0.55, which is comparable to the CPRX Sharpe Ratio of 0.76. The chart below compares the historical Sharpe Ratios of XPEL and CPRX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	XPEL	CPRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.55	0.76	-0.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.23	0.88	-1.11
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.73	0.80	-0.07
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	0.09	+0.02

Drawdowns

XPEL vs. CPRX - Drawdown Comparison

The maximum XPEL drawdown since its inception was -99.44%, which is greater than CPRX's maximum drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for XPEL and CPRX.

Drawdown Indicators

	XPEL	CPRX	Difference
Max Drawdown Largest peak-to-trough decline	-99.44%	-94.25%	-5.19%
Max Drawdown (1Y) Largest decline over 1 year	-31.79%	-27.29%	-4.50%
Max Drawdown (3Y) Largest decline over 3 years	-71.47%	-27.29%	-44.18%
Max Drawdown (5Y) Largest decline over 5 years	-75.62%	-45.37%	-30.25%
Max Drawdown (10Y) Largest decline over 10 years	-75.62%	-64.87%	-10.75%
Current Drawdown Current decline from peak	-55.36%	-0.16%	-55.20%
Average Drawdown Average peak-to-trough decline	-52.41%	-52.05%	-0.36%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.25%	14.95%	-1.70%

Volatility

XPEL vs. CPRX - Volatility Comparison

XPEL, Inc. (XPEL) has a higher volatility of 17.50% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 6.81%. This indicates that XPEL's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XPEL	CPRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.50%	6.81%	+10.69%
Volatility (6M) Calculated over the trailing 6-month period	29.42%	23.58%	+5.84%
Volatility (1Y) Calculated over the trailing 1-year period	40.52%	33.60%	+6.92%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	54.89%	47.86%	+7.03%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	63.71%	60.61%	+3.10%

Dividends

XPEL vs. CPRX - Dividend Comparison

Neither XPEL nor CPRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

XPEL vs. CPRX - Profitability Comparison

The chart below illustrates the profitability comparison between XPEL, Inc. and Catalyst Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

XPEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported a gross profit of 51.23M and revenue of 117.35M. Therefore, the gross margin over that period was 43.7%.

CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.

XPEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported an operating income of 13.01M and revenue of 117.35M, resulting in an operating margin of 11.1%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.

XPEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported a net income of 10.35M and revenue of 117.35M, resulting in a net margin of 8.8%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.

Frequently Asked Questions

Can I hold both XPEL and CPRX in my portfolio?

XPEL and CPRX have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, XPEL or CPRX?

XPEL has higher volatility (17.50%) compared to CPRX (6.81%). In terms of maximum drawdown, XPEL dropped -99.44% vs CPRX's -94.25%.

Which has better risk-adjusted returns?

CPRX currently has the higher Sharpe Ratio (0.76 vs 0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.